Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Investing.com - TD Cowen has reiterated its Buy rating and $780.00 price target on Regeneron Pharmaceuticals (NASDAQ:REGN) following meetings with the company’s management, including George Yancopoulos. According to InvestingPro data, analysts’ targets range from $543 to $815, with the stock currently trading at $569.54.
The research firm noted that discussions primarily focused on Regeneron’s pipeline, with TD Cowen expressing particular interest in the company’s allergy programs. The analyst was "impressed" with both near-term Phase III IgE data expected in the second half of the year and the long-term bispecific antibody opportunity in this therapeutic area.
TD Cowen highlighted Lynozyfic’s development for first and second-line multiple myeloma and precursor conditions as "differentiated" within the competitive landscape, suggesting potential growth opportunities in this segment.
The firm’s report also mentioned ongoing development programs in generalized myasthenia gravis (gMG), with data expected by the end of September, and LAG3 inhibitor results anticipated in early 2026.
Additional pipeline elements discussed during the management meetings included Regeneron’s obesity programs, siRNA therapeutics, and gene therapy initiatives, which TD Cowen characterized as "more going on under the hood than appreciated."
In other recent news, Regeneron Pharmaceuticals reported second-quarter results that surpassed expectations, with significant contributions from Dupixent and Libtayo products. Guggenheim responded by raising its price target for Regeneron to $815, citing strong Dupixent sales and a resilient performance from the Eylea franchise despite competitive and regulatory challenges. Eylea HD demonstrated a 16% increase in demand, although Eylea 2mg saw a 10% decline. Truist Securities also maintained a Buy rating but lowered its price target to $812, reflecting concerns over Eylea. Meanwhile, Rothschild Redburn initiated coverage with a Buy rating and set a price target of $890, indicating a potential 60% upside. Cantor Fitzgerald reiterated its Overweight rating with a $678 price target despite mixed updates, noting positive acceleration for Eylea HD. These developments highlight diverse analyst perspectives on Regeneron’s financial health and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.